Dabur India Ltd. has announced a final dividend of ₹5.50 per equity share for the financial year ended March 31, 2026. According to reports from Moneycontrol, the ex-date for this dividend is set for tomorrow, July 17, 2026, with the record date also being the same. The company had announced this dividend on May 7, 2026, providing shareholders with adequate time to plan their participation in the distribution. Registered shareholders who own Dabur India's shares on or before the record date of July 17, 2026 are eligible to receive the dividend, while those purchasing shares on or after this date will not be entitled to the payout.
Dabur India's latest quarterly results demonstrate robust performance with double-digit growth in consolidated sales after a gap of 11 quarters. As reported by Business Standard, this growth was led by high-teens growth in the international business and near-double-digit growth in the India business. In the domestic market, Q1FY27 volumes are expected to rise 7% year-on-year, compared with a 6% increase in Q4FY26 and a 1% decline in Q1FY26, driven by improving demand trends and rural segment outpacing urban growth. The home and personal care (HPC) segment was the outperformer, registering growth in the high single digits, with hair oils and shampoos expected to grow in the high teens.
Based on the current share price of ₹431.30, this final dividend translates to a dividend yield of approximately 1.27%. As reported by Moneycontrol, including this final dividend, the total annual dividend for fiscal year 2026 stands at ₹8.25 per share, demonstrating the company's commitment to consistent shareholder returns. The stock was trading at ₹431.30 today, recording a decline of 0.73% from its previous close, with the company maintaining a market capitalization of ₹76,510.57 crore. Shareholders can expect to receive Dabur India's dividend in their bank account linked to their Demat account within 25 to 45 business days after the record date of July 17, 2026.
The healthcare segment is likely to improve sequentially with mid-single-digit growth, as strong double-digit growth in Hajmola, Pudin Hara, Health Juices, Dabur Honitus and Isabgol is partly offset by weakness in Dabur Glucose. The foods business is expected to sustain double-digit growth, with the Badshah portfolio growing in the high teens, while the beverages portfolio is likely to recover sequentially, supported by double-digit growth in Real Activ and coconut water. The international business is likely to grow 17% in rupee terms and 11-12% in constant currency, with Egypt, Turkey, Bangladesh and the UK reporting strong double-digit growth despite continued geopolitical headwinds in West Asia. Despite positive corporate actions, shares saw a slight downturn today, trading at ₹431.30 with a 0.73% decline.
While double-digit sales growth is positive, it is slower than peers such as Marico and GCPL, with analysts noting that more work needs to be done to accelerate growth in healthcare and beverages portfolios. As reported by Business Standard, valuations at 39 times FY27 and 34 times FY28 earnings estimates are not demanding. JM Financial Research has retained its 'add' rating with a target price of ₹505, while Nuvama Research expects net profit to grow 12% year-on-year and maintains a 'buy' rating with a target price of ₹620. However, analysts emphasize that rerating to the long-term average will be contingent on more consistent delivery, especially on the revenue front.
